A new lightweight, gel-free, waterproof wireless heart monitor invented at RMIT University is moving from the lab into a clinical trial in Perth. Australian startup Lubdub is developing it to give doctors the same kind of detailed heart rhythm data they get from a medical-grade ECG Holter monitor.
Patients who have already been prescribed a Holter monitor will wear the prototype patch as well in a trial that started this week at Midlands Medical Specialists in Western Australia. Lubdub says the device can track the heart’s rhythm continuously for up to 14 days as people go about their daily activities.
The patch is meant to stay comfortable for days at a time
RMIT Professor and Lubdub co-founder Sharath Sriram said earlier testing with healthy volunteers found the prototype was comfortable to wear and produced promising results. “The flexible sensors make better contact with the skin than those used in traditional Holter monitors,” he said. The university says the data collected by the patch was 18 times cleaner than the readings from traditional Holter monitors.
Sriram also said that reducing the work needed to generate cardiac reports could let the same workforce monitor up to 85 percent more patients even before other tools like AI are added. The trial will gather evidence for further development and possible regulatory approval.
Lubdub wants to combine several heart tests in one platform
The ECG patch is the first of three heart-monitoring technologies the company plans to bring together in a single software platform alongside biomarker technologies testing and wearable ultrasound imaging. RMIT recently licensed the intellectual property for the ECG and biomarker to Lubdub.
Sriram said early symptoms of heart disease are often missed even though cardiovascular disease is responsible for a third of deaths globally and nearly a quarter in Australia. “Our innovation is about simpler and more effective screening, because prevention is better than cure,” he said.
The Heart Foundation chose Lubdub as one of its 10 most promising heart health projects for 2026. In September, the company announced an oversubscribed $6 million seed funding round, doubling its original $3 million target, with backing mainly from physicians and heart specialists.
Co-founder and director Nikhilesh Bappoo has a personal stake in making those tests easier to reach. After his father suffered a heart attack in Perth and received timely specialist care, he thought about the more limited access in Mauritius, where he grew up. “Had it happened there, the outcome could have been very different,” he said.
Related Coverage
